Atea Pharmaceuticals (AVIR) Other Non-Current Liabilities (2019 - 2025)

Atea Pharmaceuticals' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $6.8 million for Q3 2025.

• In Q3 2025, Other Non-Current Liabilities rose 9.58% year-over-year to $6.8 million; the TTM figure through Sep 2025 stood at $6.8 million (up 9.58% YoY), while the FY2024 annual figure was $6.4 million, up 10.39% from the prior year.
• Other Non-Current Liabilities for Q3 2025 stood at $6.8 million, up from $6.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $6.8 million in Q3 2025, with the low at $29000.0 in Q2 2021.
• The 5-year median for Other Non-Current Liabilities is $5.9 million (2021), against an average of $5.3 million.
• Peak annual rise in Other Non-Current Liabilities reached 20617.24% in 2022, while the deepest fall reached 11.41% in 2022.
• Atea Pharmaceuticals' Other Non-Current Liabilities stood at $5.9 million in 2021, then retreated by 11.41% to $5.3 million in 2022, then climbed by 9.57% to $5.8 million in 2023, then rose by 10.39% to $6.4 million in 2024, then climbed by 6.91% to $6.8 million in 2025.
• Business Quant data shows AVIR's Other Non-Current Liabilities at $6.8 million in Q3 2025, $6.6 million in Q2 2025, and $6.5 million in Q1 2025.